ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock News
NASDAQ:ARCT - Nasdaq - US03969T1097 - Common Stock - Currency: USD
ARCT Latest News, Press Relases and Analysis
Which stocks are moving before the opening bell on Tuesday?
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Which stocks are moving after the closing bell on Monday?
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Take-Two Interactive Stock Slips After 'GTA 6' Maker's Outlook Comes Up Short
Take-Two Interactive reported fiscal fourth-quarter revenue that topped analysts’ expectations, but the gaming company's net loss and forecast disappointed.
AMAT Earnings: Demand Holding Up So Far
Applied Materials beat analyst expectations for earnings but missed on revenue. The company said that customer demand hasn’t changed due to an uncertain economic environment. Applied Materials’ outlook for the third quarter included wide ranges for revenue and adjusted earnings per share.
Cava: Rapid Growth but Some Concerns
Fast-casual restaurant company Cava reported revenue and earnings that handily beat expectations. Same-restaurant sales growth of 10.8% was especially impressive. The company's forecast calls for same-restaurant sales growth to decelerate as the year goes on.
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 67.09% and 3.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BOLT
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: TECH
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the...
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
